TGTXTG THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- $616M
- 87% YoY
- Operating margin
- 20.0%
- 57% YoY
- EBITDA
- $123M
- 194% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -3.1×
- −$382M net debt
- AI in 10-K
- —
Red flags 2 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-6% of net incomeCash flow under 80% of net income
- Dilutive SBCFired10% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $7M | $3M | $234M | $329M | $616M | 87% |
| Operating income | −$345M | −$218M | $21M | $42M | $123M | 194% |
| Net income | −$348M | −$198M | $13M | $23M | $447M | 1811% |
| Operating cash flow | −$296M | −$176M | −$31M | −$41M | −$25M | 39% |
| Capex | $401K | $14K | $0 | $45K | $214K | 376% |
| Stock-based comp | $61M | $45M | $38M | $43M | $65M | 52% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $275K · 1
- Net
- −$275K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $26M | $28M | 57 | 120 |
| FY2024 | $19M | $92M | 58 | 91 |
| FY2023 | $18M | $41M | 33 | 92 |
| FY2022 | $10M | −$43M | 23 | 89 |
| FY2021 | $43M | −$114M | 37 | 99 |